Work

Testicular cancer in 2023: Current status and recent progress

Year: 2023

Type: article

Abstract: Testicular germ cell tumor (GCT) is the most common solid tumor in adolescent and young adult men. Progress in the management of GCT has been made in the last 50 years, with a substantial improvement in cure rates for advanced disease, from 25% in the 1970s to nearly 80%. However, relapsed or platinum-refractory disease occurs in a proportion, 20% of whom will die from disease progression. This article reviews the current evidence-based treatments for extracranial GCT, the acute and chronic toxic effects that may result, and highlights contemporary advances and progress in the field.

Source: CA A Cancer Journal for Clinicians

DOI: 10.3322/caac.21819

Authors: Deaglan J. McHugh, Jack P. Gleeson, Darren R. Feldman

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, University College Cork, Cork University Hospital

Language: English

Topic: Testicular diseases and treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,330